ArticleACS omega2026
The Dual-Integrated Multi-Attribute Method: Simultaneous Evaluation of Post-Translational Modifications and Host Cell Proteins for Unpurified Bulk Harvest of Antibody Therapeutics.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- System Performance Check (SPC): A Readiness Companion to Multi-Attribute Method (MAM) Analysis in Biopharmaceutical Quality Control.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Multi-Attribute Method (MAM) using liquid chromatography/mass spectrometry (LC/MS) is widely applied to evaluate post-translational modifications (PTMs) in antibody therapeutics. This approach allows the monitoring of multiple PTMs within a single method. In this study, we extended the scope of MAM by incorporating host cell proteins (HCPs) as additional targets and developed a dual, integrated PTMs-HCPs MAM platform. This platform enables the simultaneous evaluation of more comprehensive critical quality attributes through a combination of MS1-based PTMs analysis and data-independent acquisition-based HCP quantification. Although proteomics-based characterization of residual HCPs has been extensively reported, prior studies have primarily focused on purified drug substances or products. Here, we demonstrate the application of our integrated platform to unpurified bulk harvest samples, eliminating the need for purification. While conventional PTMs-MAM and HCP-proteomics are typically conducted separately on purified samples, our dual integrated-MAM approach allows the linking of antibody PTMs with their potential HCP influencers within a single LC/MS injection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.